Cargando…
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: statistical analysis plan for a randomised controlled trial (UPGRADE trial)
BACKGROUND: Approximately 8–15% of patients undergoing bariatric surgery develop symptomatic gallstone disease within 24 months after surgery. Ursodeoxycholic acid (UDCA) seems to effectively prevent the formation of gallstones detectable by ultrasound after bariatric surgery. The aim of the UPGRADE...
Autores principales: | Haal, Sylke, Guman, Maimoena S. S., de Brauw, L. Maurits, van Veen, Ruben N., Schouten, Ruben, Fockens, Paul, Gerdes, Victor E. A., Dijkgraaf, Marcel G. W., Voermans, Rogier P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376318/ https://www.ncbi.nlm.nih.gov/pubmed/32703246 http://dx.doi.org/10.1186/s13063-020-04605-7 |
Ejemplares similares
-
Cost-effectiveness of ursodeoxycholic acid in preventing new-onset symptomatic gallstone disease after Roux-en-Y gastric bypass surgery
por: Haal, Sylke, et al.
Publicado: (2022) -
Risk Factors for Symptomatic Gallstone Disease and Gallstone Formation After Bariatric Surgery
por: Haal, Sylke, et al.
Publicado: (2022) -
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial)
por: Boerlage, Thomas C. C., et al.
Publicado: (2017) -
Ursodeoxycholic Acid Use After Bariatric Surgery: Effects on Metabolic and Inflammatory Blood Markers
por: Guman, Maimoena S. S., et al.
Publicado: (2023) -
Gallstone Formation Follows a Different Trajectory in Bariatric Patients Compared to Nonbariatric Patients
por: Haal, Sylke, et al.
Publicado: (2021)